Transimmune AG is leading a revolution in dendritic cell therapy having uncovered how dendritic cells are made physiologically in vivo.
| Website | http://www.transimmune.com |
| Revenue | $3 million |
| Employees | 4 (4 on RocketReach) |
| Address | 90 Königsallee, Düsseldorf, North Rhine-Westfalia 40212, DE |
| Phone | +49 4921 164136110 |
| Industry | Biotechnology Research, Business Services General, Business Services |
| Keywords | Immunotherapy, Cell Therapy, Immunology, Immune Response, Cell-Based Therapy, Oncology, In Vivo, Cancer Immunotherapy, Cancer Treatment, Biotechnology, Precision Medicine, Therapeutic Vaccines, Advanced Therapies, Pharmaceutical, Drug Development, Biological Therapies, Clinical Trials, Regenerative Medicine |
| Competitors | Roche, Novartis, Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Regeneron, Gilead Sciences, Lilly India +46 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies |
Looking for a particular Transimmune AG employee's phone or email?
The Transimmune AG annual revenue was $3 million in 2026.
Justin Duckworth is the CEO of Transimmune AG.
4 people are employed at Transimmune AG.
Transimmune AG is based in Düsseldorf, North Rhine-Westfalia.
The NAICS codes for Transimmune AG are [54, 5417, 54171, 541, 541714].
The SIC codes for Transimmune AG are [873, 87].